Pulmatrix (NASDAQ:PULM) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Pulmatrix, Inc. (NASDAQ:PULM)’s share price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.11 and traded as low as $1.2710. Pulmatrix shares last traded at $1.38, with a volume of 177,492 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a research report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pulmatrix presently has a consensus rating of “Sell”.

Pulmatrix Stock Up 2.6%

The company has a market cap of $5.04 million, a price-to-earnings ratio of -0.98 and a beta of 1.97. The business’s fifty day simple moving average is $1.98 and its two-hundred day simple moving average is $3.11.

Pulmatrix (NASDAQ:PULM) last issued its earnings results on Thursday, February 26th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP bought a new stake in Pulmatrix, Inc. (NASDAQ:PULM) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned about 0.30% of Pulmatrix as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 11.84% of the company’s stock.

Pulmatrix Company Profile

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).